106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. (December 2022) - L. Zuo,; Zhou, S.; Liu, P.; Yang, S.; Yang, J.; He, X.; Gui, L.; Li, R.; Yang, Y.